Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Reminyl name change no remedy

Executive Summary

Pharmacists are reporting confusion between Takeda's sleep aid Rozerem (ramelteon) and J&J's Alzheimer's therapy Razadyne (galantamine), according to the Institute for Safe Medication Practice's Medication Safety Alert. Name confusion is not a new problem for the J&J product; formerly Reminyl, the company renamed galantamine Razadyne in 2005 due to confusion with Sanofi-Aventis' anti-diabetic Amaryl (glimepiride) (1"The Pink Sheet" Jan. 10, 2005, p. 8)...

You may also be interested in...

Reminyl Name Change Gives J&J Fresh Message For Galantamine ER Launch

Janssen's name change for its Reminyl Alzheimer's products gives the company a fresh platform for promoting the galantamine extended-release formulation approved by FDA Dec. 22

Device Week, 05 March - Remote Monitoring Reimbursement, T-cell Diagnostics And A Digital Health Feature

In this week's podcast, managing editor Marion Webb discusses a new monthly digital health roundup which will soon feature on Medtech Insight. Managing editor Reed Miller discusses reimbursement difficulties as it applies to remote cardiac monitoring. UK-based reporter Barnaby Pickering gives an overview of an interview with the chief medical officer of Adaptive Biotechnologies about its new T-Detect platform.

Coronavirus Notebook: Italy Makes First Use Of EU’s Vaccine Export Control System, More Regulators Issue Guidance On Variants

Ukraine has established a system for issuing emergency use authorizations for COVID-19 vaccines that recognizes authorizations granted by other world regulators.




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts